R., De Jonghe, B
Patients should have regular follow-up appointments to monitor effectiveness, manage side effects, and assess whether continued treatment is appropriate
Until VK2735 completes phase 3 development and achieves regulatory approval, semaglutide remains the clear recommendation for clinical use
CMS extended the Bridge to December 31, 2027 to fill the gap, but what follows after that remains unresolved
What specific steps can the government take to address the opportunities presented by the GLP-1 class of drugs
Toki S, Newcomb DC, Printz RL, Cahill KN, Boyd KL, Niswender KD, et al